Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Posttransplant monomorphic Burkitt's lymphoma: clinical characteristics and outcome of a multicenter series.
Bobillo S, Abrisqueta P, Sánchez-González B, Giné E, Romero S, Alcoceba M, González-Barca E, González de Villambrosía S, Sancho JM, Gómez P, Bento L, Montoro J, Montes S, López A, Bosch F; Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group). Bobillo S, et al. Ann Hematol. 2018 Dec;97(12):2417-2424. doi: 10.1007/s00277-018-3473-8. Epub 2018 Aug 16. Ann Hematol. 2018. PMID: 30116871 Clinical Trial.
Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
Sanchez-Gonzalez B, Peñalver FJ, Medina A, Guillén H, Calleja M, Gironella M, Arranz R, Sebastian E, de Oña R, Cánovas A, de la Fuente I, Grande C, Sancho JM, Perez R, Domingo E, Lopez-Lorenzo JL, Prieto E, Panizo C, Gorosquieta A, Perez I, Cervera JM, Marin M, Mencha C, Ramila E, Salar A. Sanchez-Gonzalez B, et al. Leuk Res. 2012 Jun;36(6):709-14. doi: 10.1016/j.leukres.2011.10.024. Epub 2011 Dec 7. Leuk Res. 2012. PMID: 22154023
Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome.
Muñiz C, Martín-Martín L, López A, Sánchez-González B, Salar A, Almeida J, Sancho JM, Ribera JM, Heras C, Peñalver FJ, Gómez M, González-Barca E, Alonso N, Navarro B, Olave T, Sala F, Conde E, Márquez JA, Cabezudo E, Cladera A, García-Malo M, Caballero MD, Orfao A; Spanish Group for the Study of Central Nervous System Disease in Non-Hodgkin Lymphoma. Muñiz C, et al. Blood. 2014 Mar 20;123(12):1864-9. doi: 10.1182/blood-2013-11-537993. Epub 2014 Feb 5. Blood. 2014. PMID: 24501214 Free article.
Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma.
Wilson WH, Bromberg JE, Stetler-Stevenson M, Steinberg SM, Martin-Martin L, Muñiz C, Sancho JM, Caballero MD, Davidis MA, Brooimans RA, Sanchez-Gonzalez B, Salar A, González-Barca E, Ribera JM, Shovlin M, Filie A, Dunleavy K, Mehrling T, Spina M, Orfao A. Wilson WH, et al. Haematologica. 2014 Jul;99(7):1228-35. doi: 10.3324/haematol.2013.101741. Epub 2014 Apr 11. Haematologica. 2014. PMID: 24727817 Free PMC article.
Bendamustine as salvage treatment for patients with relapsed or refractory mantle cell lymphoma patients: a retrospective study of the Spanish experience.
García-Noblejas A, Martínez Chamorro C, Navarro Matilla B, Da Silva Rodriguez C, González-Lopez TJ, Oña Navarrete R, Ramírez Sánchez MJ, Martínez Barranco P, Sánchez Blanco JJ, Nicolás C, Pérez R, Sánchez González B, Ruedas López AM, Domingo-Domenech E, Panizo C, Macia S, Fernández-Fonseca E, Cannata-Ortiz J, Arranz R. García-Noblejas A, et al. Ann Hematol. 2014 Sep;93(9):1551-8. doi: 10.1007/s00277-014-2077-1. Epub 2014 Apr 30. Ann Hematol. 2014. PMID: 24782117
Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: results of the PRO-R-IPI study.
Panizo C, Rodríguez AJ, Gutiérrez G, Díaz FJ, González-Barca E, de Oña R, Grande C, Sancho JM, García-Álvarez MF, Sánchez-González B, Peñalver FJ, Cannata J, Espeso M, Requena MJ, Gardella S, Durán S, González AP, Alfonso A, Caballero MD; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea GELTAMO Spanish Cooperative Group. Panizo C, et al. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):398-403. doi: 10.1016/j.clml.2015.02.029. Epub 2015 Mar 5. Clin Lymphoma Myeloma Leuk. 2015. PMID: 25843416 Clinical Trial.
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C. Garcia-Sanz R, et al. Ann Oncol. 2019 Apr 1;30(4):612-620. doi: 10.1093/annonc/mdz009. Ann Oncol. 2019. PMID: 30657848 Free article. Clinical Trial.
Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group.
Muntañola A, Baumann T, Caballero AC, Sánchez-González B, Mercadal S, Escoda L, Soler A, Iserte L, Canet M, Villalobos MT, Magnano L, Sorigué M, García O, Salar A, López-Guillermo A, Sancho JM. Muntañola A, et al. Ann Hematol. 2020 Jul;99(7):1627-1634. doi: 10.1007/s00277-020-04101-7. Epub 2020 May 25. Ann Hematol. 2020. PMID: 32451707
SEGHI Study: Defining the Best Surveillance Strategy in Hodgkin Lymphoma after First-Line Treatment.
Bastos Oreiro M, Martín R, Gomez P, López Muñoz N, Rodriguez A, Liébana M, Navarro B, Sánchez-González B, Marí P, Pérez de Oteiza J, Gutiérrez A, Bento L, Domingo Doménech E, Vidal MJ, Del Campo R, Pérez Ceballos E, Infante M, Roldán A, García Belmonte D, Santero M, Sureda A, Sanz RG, On Behalf Of The Geltamo Group. Bastos Oreiro M, et al. Cancers (Basel). 2021 May 17;13(10):2412. doi: 10.3390/cancers13102412. Cancers (Basel). 2021. PMID: 34067616 Free PMC article.
86 results